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Abstract
The orphan receptor sigma-1 (sigmar-1) is a transmembrane chaperone protein expressed in both the central nervous
system and in immune cells. It has been shown to regulate neuronal differentiation and cell survival, and mediates anti-
inflammatory responses and immunosuppression in murine in vivo models. Since the details of these findings have not
been elucidated so far, we studied the effects of the endogenous sigmar-1 ligands N,N-dimethyltryptamine (NN-DMT), its
derivative 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and the synthetic high affinity sigmar-1 agonist PRE-084
hydrochloride on human primary monocyte-derived dendritic cell (moDCs) activation provoked by LPS, polyI:C or
pathogen-derived stimuli to induce inflammatory responses. Co-treatment of moDC with these activators and sigma-1
receptor ligands inhibited the production of pro-inflammatory cytokines IL-1b, IL-6, TNFa and the chemokine IL-8, while
increased the secretion of the anti-inflammatory cytokine IL-10. The T-cell activating capacity of moDCs was also inhibited,
and dimethyltryptamines used in combination with E. coli or influenza virus as stimulators decreased the differentiation of
moDC-induced Th1 and Th17 inflammatory effector T-cells in a sigmar-1 specific manner as confirmed by gene silencing.
Here we demonstrate for the first time the immunomodulatory potential of NN-DMT and 5-MeO-DMT on human moDC
functions via sigmar-1 that could be harnessed for the pharmacological treatment of autoimmune diseases and chronic
inflammatory conditions of the CNS or peripheral tissues. Our findings also point out a new biological role for
dimethyltryptamines, which may act as systemic endogenous regulators of inflammation and immune homeostasis through
the sigma-1 receptor.
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Introduction
The term sigma receptor dates back historically to the sigma/
opioid receptor described by Martin et al. [1] and reported to
mediate the psychotropic effects of N-allylnormetazocine
(NANM). It was originally thought to be an opioid receptor due
to its modulation by NANM that could be antagonized by
naloxone, a universal opioid antagonist [2]. Later, Su and
colleagues clarified the pharmacological features of the ligand-
binding site and the name was changed to ‘sigma receptor’
differentiating it from the sigma/opioid receptor [3,4]. According
to its tissue expression profile and ligand selectivity the receptor
was subsequently classified to the sigma-1 and sigma-2 receptor
subtypes (sigmar-1/2) [5]. In the last two decades several clinical
studies demonstrated the importance of sigmar-1 in many diseases
ranging from cancer, pain and addiction to different psychiatric
and neurological disorders among them Major depression,
Alzheimer’s disease, schizophrenia, and stroke [2].
Early studies showed that sigmar-1 is expressed not only in
distinct regions of the CNS but also in immune cells [4,6]. It was
shown to regulate cell differentiation and survival by acting as a
chaperone at the mitochondria-associated endoplasmic reticulum
membrane [7,8]. Murine studies also demonstrated that the
specific activation of sigmar-1 resulted in immunosuppression [9],
and in vivo decreased lymphocyte activation and proliferation
[10]. Sigma-1 receptor ligands possess potent immunoregulatory
properties via increasing the secretion level of anti-inflammatory
IL-10 [11], and suppressing IFNc and GM-CSF expression [10].
These important studies showed that sigmar-1 may cause
significant alterations in immune functions.
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The endogenous ligands for sigmar-1 involve neurosteroids,
dehydroepiandrosterone (DHEA), and naturally occuring indole
alkaloids/tryptamines, such as N,N-dimethyltryptamine (NN-
DMT) and its closely related analogue 5-methoxy-N,N-dimethyl-
tryptamine (5-MeO-DMT). Hallucinogen indole alkaloids are
widespread in nature and abundant in plants, which are used in
preparation of sacramental psychoactive decoctions such as yage
and ayahuasca [12]. NN-DMT and 5-MeO-DMT have also been
detected in animal tissues; furthermore, NN-DMT is considered as
an endogenous trace amine neurotransmitter that regulates brain
physiology [13–15]. It has recently been shown that NN-DMT is a
natural ligand for sigmar-1 [16], and its administration was
reported to influence the number of circulating lymphocytes in
humans, but the exact mechanism has not been uncovered yet
[17]. In the light of these findings it is tempting to speculate that
NN-DMT and 5-MeO-DMT may have impact on inflammatory
responses through sigmar-1 [12].
Dendritic cells (DCs) are key players of innate immunity in
higher vertebrates and their most prominent functions involve the
continous sampling of the neighbouring enviroment. Harboring a
selected spectrum of pathogen-sensing pattern recognition recep-
tors (PRRs), such as intracellular Toll-like receptors (TLRs) and
RIG-I-like receptors (RLRs), they can be activated by specific self
and non self ligands [18]. They also exhibit the unique and crucial
ability to translate PRR-mediated signals to adaptive immunity,
thereby orchestrating natural and acquired immune responses
[19]. Specialized subsets of DCs are working together as a network
of vigilant gatekeepers in literally all tissues of the body [20]. In
vitro differentiated human monocyte-derived DCs (moDCs) are
considered as gold standards of DC biology and are used in
various clinical and experimental settings [21]. Since human
monocytes have recently been shown to migrate to the brain and
are able to modulate the neuroinflammatory profile of the CNS
[22], moDCs may represent a cell type, which, besides microglia,
could also contribute to the immunoregulation of the neural tissue.
In this study we aimed to investigate the effects of NN-DMT and 5-
MeO-DMT-mediated activation of sigmar-1 on human primary
moDC functions under inflammatory conditions as compared to
resting state. To our best knowledge this is the first study reporting
that dimethyltryptamines are potent anti-inflammatory agents, which
have the capacity to modulate the functions of moDCs in a sigmar-1-
dependent manner. Our results envision that dimethyltryptamines
targeted to the sigmar-1 receptor could emerge as promising
candidates for future pharmacological therapies in chronic inflam-
matory and autoimmune conditions of the CNS or peripheral tissues.
We also propose a new biological role for NN-DMT, which, through
the sigmar-1 of myeloid immune cells, may act as an endogenous
regulator of inflammation and immune homeostasis.
Materials and Methods
Cell isolation and culturing
Leukocyte-enriched buffy coats were obtained from healthy
blood donors drawn at the Regional Blood Center of the
Hungarian National Blood Transfusion Service (Debrecen,
Hungary) in accordance with the written approval of the Director
of the National Blood Transfusion Service and the Regional and
Institutional Ethics Committee of the University of Debrecen,
Faculty of Medicine (Debrecen, Hungary). Written informed
consent was obtained from the donors prior blood donation, and
their data were processed and stored according to the directives of
the European Union. Peripheral blood mononuclear cells
(PBMCs) were separated by a standard density gradient centrifu-
gation with Ficoll-Paque Plus (Amersham Biosciences, Uppsala,
Sweden). Monocytes were purified from PBMCs by positive
selection using immunomagnetic cell separation with anti-CD14
microbeads according to the manufacturer’s instruction (Miltenyi
Biotech, Bergisch Gladbach, Germany). After separation on a
VarioMACS magnet, 96–99% of the cells were CD14+ monocytes
as measured by flow cytometry. Monocytes were cultured in 12-
well tissue culture plates at a density of 26106 cells/ml in serum-
free AIMV medium (Invitrogen, Carlsbad, CA) supplemented
with 80 ng/ml GM-CSF (Gentaur Molecular Products, Brussels,
Belgium) and 100 ng/ml IL-4 (Peprotech EC, London, U.K.). On
day 2, the same amounts of GM-CSF and IL-4 were added to the
cell cultures without changing their media.
Autologous naive T-cells were separated from mononuclear
cells of the same donor using human naive CD4+ T Cell Isolation
Kits (Miltenyi Biotech).
Activation of dendritic cells
Bacterial lipopolysaccharide (LPS) (Sigma, Schnelldorf, Germany),
and high molecular weight polyinosinic: polycytidylic acid (polyI:C)
(InvivoGen, San Diego, CA) were used at working concentrations of
500 ng/ml (LPS) and 20 mg/ml (polyI:C), respectively. N,N-dimeth-
yltryptamine (R&D Systems, Abingdon, UK), 5-methoxy-N,N-
dimethyltryptamine (Sigma), and 2-(4-morpholinoethyl-1)-phenylcy-
clohexane-1-carboxylate hydrochloride (PRE084) (Tocris Bioscience,
Bristol, UK) were used in a working concentration of 100 mM. Pre-
treatments were performed 1 h prior to DC activation. Controlled
substances (Schedule I drugs) were used with the approval and
monitoring of the Hungarian Institute for Forensic Sciences and the
Hungarian National Police Department.
Purified and inactivated A/Brisbane/59/7 (H1N1) influenza
virus (kindly provided by the National Center for Epidemiology,
Hungary) of 66106 PFU/mL was used for in vitro treatment of
16106 per mL DC in serum-free AIMV medium for 24 h.
Activated cells were washed two times in sterile medium and then
co-cultured with autologous naive T cells (ELISPOT).
For activation of cells with bacteria, 56104 heat-killed
Escherichia coli 058 (Institute of Microbiology and Virology of
National Academy of Science, Hungary) was added to 105 moDCs
in 300 ml medium on a 96 well plate and incubated at 37uC for
24 h prior to ELISPOT assay. MoDCs were washed two times in
sterile AIMV before co-culturing, as above.
To prepare cell lysates for Western blotting, or collect supernatants
for ELISA cells were activated for 24 h. Cell lysates were made after
8 h for Q-PCR measurements (if not stated otherwise).
RNA isolation, cDNA synthesis and QPCR
Real-time quantitative polymerase chain reaction (QPCR) was
performed as described previously [23]. Briefly, total RNA was
isolated by TRIzol reagent (Invitrogen, Carlsbad, CA). 1.5–2 mg of
total RNA were reverse transcribed using SuperScript II RNase H
reverse transcriptase (Invitrogen) and Oligo (dT) 15 primers
(Promega, Madison, WI). Gene-specific TaqMan assays (Applied
Biosystems, Foster City, CA) were used to perform QPCR in a
final volume of 12 ml in triplicates using AmpliTaq Gold DNA
polymerase and ABI StepOnePlus real-time PCR instrument
(Applied Biosystems). Amplification of 36B4 was used as a
normalizing control. Cycle threshold values (Ct) were determined
by using the StepOne 2.1 software. Constant threshold values were
set for each gene throughout the study. Details of TaqMan assays
are shown in Table S1.
Cytokine measurements
Culture supernatants were harvested 24 hours after activation
and the concentrations of IL-1b, IL-6, TNFa, IL-8, and IL-10
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Figure 1. Expression of the Sigma-1 receptor in human monocytes, and differentiated monocyte-derived macrophages (moMACs)
and dendritic cells (moDCs). A–B: Expression of sigmar-1 protein in monocytes, and differentiated moMACs and moDCs measured by Western
blot. In Fig1A a typical experiment out of four is demonstrated. Densitometry data of Fig1B show the Mean 6 SEM values of four independent
donors. C: Time kinetics of sigmar-1 gene expression in non-activated control (ctrl), 20 mg/ml polyI:C (polyI:C) or 500 ng/ml LPS (LPS) treated cells.
Data of triplicates of four independent measurements are show as Mean6 SEM. D–E: Sigmar-1 protein expression in non-activated control, 20 mg/ml
polyI:C or 500 ng/ml LPS treated cells following 24 hours of activation. In Fig1D, results of a typical experiment out of four is shown. Densitometry
data of Fig1E show the Mean 6 SEM values of four independent donors. (*) represents p values,0.05. (n.s.: ‘‘non-significant’’).
doi:10.1371/journal.pone.0106533.g001
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Figure 2. Effects of NN-DMT and 5-MeO-DMT treatment on the gene expression and secretion of cytokines and chemokines in LPS-
stimulated moDCs. A: MoDCs were incubated with 100 mM NN-DMT (NN-DMT) or 5-MeO-DMT (5-MeO-DMT) for 8 h or left untreated (ctrl) were
used as controls. Additionally, cells were either activated with 500 ng/ml LPS alone for 8 h, or pre-treated with tryptamines for 1 hour and
subsequently were activated with LPS for 8 hours (LPS+NN-DMT; LPS+5-MeO-DMT). The expression of IL-1b, TNFa, IL-6, IL8, and IL-10 was assessed by
real-time Q-PCR and shown as relative mRNA expression. Results represent the Mean 6 SEM of 4 independent experiments. B: Cytokine profile of
cells treated as above. Supernatants of DC cultures were collected after 24 h and were subjected to ELISA measurements. Concentration of the
secreted cytokines and chemokines are shown as Mean 6 SEM values of 4 independent donors. (*) means statistical significance as p,0.05.
doi:10.1371/journal.pone.0106533.g002
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Figure 3. Effects of NN-DMT and 5-MeO-DMT treatment on the gene expression and secretion of cytokines and chemokines in
polyI:C-activated moDCs. A: MoDCs were treated as in Figure 2. In this case, cell activation was induced with 20 mg/ml polyI:C for 8 h (alone, or
subsequently to an 1 h 100 mM NN-DMT or 5-MeO-DMT pre-treatment). The expression of IL-1b, TNFa, IL-6, IL8, and IL-10 was assessed by real-time
Q-PCR and shown as relative mRNA expression. Results represent the Mean 6 SEM of 4 independent experiments. B: Cytokine profile of cells treated
as in Fig3A. Supernatants of DC cultures were collected after 24 h and were measured by ELISA. Concentration of the secreted cytokines and
chemokines are shown as Mean 6 SEM values of 4 independent donors. (*) means statistical significance as p,0.05.
doi:10.1371/journal.pone.0106533.g003
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cytokines were measured using OptEIA kits (BD Biosciences, San
Jose, CA) following the manufacturer’s recommendations. The
precision of the kits were the following: Intra-Assay variation:
CV,10%; Inter-Assay variation: CV,12% (CV% = SD/
meanX100). In each cases non-diluted supernatant samples were
used for the assays, except IL-6 (3X dilution) and IL-8 (6X
dilution) measurements.
Western blotting
Cells were lysed in Laemmli buffer and the protein extracts were
tested by Ab specific for OPRS1/Sigmar-1 (Abcam, Cambridge,
UK), and b-actin (Sigma) diluted at 1:500 and 1:000, respectively.
Anti-rabbit Ab conjugated to horseradish peroxidase (GE
Healthcare, Little Chalfont Buckinghamshire, UK) was used as
the secondary Ab at a dilution of 1:5000. The SuperSignal
enhanced chemiluminescence system was used for probing target
proteins (Thermo Scientific, Rockford, IL). After the membranes
had been probed for OPRS1/Sigmar-1, they were stripped and
re-probed for b-actin.
ELISPOT assay
Activated, pathogen-loaded DCs (26105 cells/well) were co-
cultured with naı¨ve autologous CD4+ T cells (106 cells/well) in
serum-free AIMV medium for 4 days at 37uC in humidified
atmosphere containing 5% CO2. Phytohaemagglutinin (PHA) and
Concanavalin A (ConA) activated T cells were used as positive
controls, non-treated DC+T cell co-cultures and T cells without
DC served as negative controls. Detection of activated, cytokine
secreting CD4+ T cells producing IFNc or IL17 was performed by
the avidin-horseradish peroxidase system (NatuTec). Plates were
analyzed on ImmunoScan plate reader (CTL Ltd., Shaker
Heights, OH).
RNA interference
Gene-specific siRNA knockdown was performed by Silencer
Select siRNA (Applied Biosystems) transfection using Gene Pulser
Xcell instrument (Bio-Rad, Hercules, CA). Pulse conditions were
square-wave pulse, 500 V, 0.5 ms. Immediately after electropora-
tion, cells were transferred to fresh AIMV medium supplemented
with, penicillin, streptomycin, and L-glutamine in addition to GM-
CSF and IL-4. Silencing of sigmar1 gene expression was
performed by using a mix of three of the available SIGMAR1
siRNAs. Silencer negative control nontargeting siRNA (Applied
Biosystems) was used as a negative control. The efficacy of siRNA
treatments was tested two days post-transfection by Western
blotting.
Statistical analysis
Data are presented as mean 6 SEM. A t-test was used for
comparison of two groups. One-way ANOVA, followed by
Bonferroni post hoc test, was used for multiple comparisons.
Figure 4. NN-DMT and 5-MeO-DMT pre-treatment of pathogen-activated human dendritic cells effectively inhibit their capacity to
prime autologous naive T helper 1 and T helper 17 cells. Dendritic cells were activated either by heat-killed E. coli (E. coli) or inactivated
influenza virus (IV) for 24 h, washed, and then co-cultured with naive autologous CD4+ T lymphocytes for 4 days. The number of primed, IFNc or IL-
17 secreting T cells was assessed by ELISPOT assay. T cells alone (T-cell ctrl), and non-activated DCs treated with DMT and co-cultured with
autologous naive CD4+ T lymphocytes (NN-DMT, 5-MeO-DMT) were used as controls. A–B: Induction of IFNc (A) or IL-17 (B) production of autologous
naive CD4+ T cells induced by moDC loaded by E. coli. Bacteria alone (E. coli; red bars) or bacteria in combination with 1 h DMT pre-treatment (E. coli
+ NN-DMT, E. coli+5-MeO-DMT; empty bars) were used to activate moDCs as written above. C–D: Cells were activated as in Fig4A–B; in this case
inactivated influenza virus (IV) was added to the moDCs alone for 24 h (blue bars), or in combination with an 1 h NN-DMT or 5-MeO-DMT pre-
treatment (IV + NN-DMT, IV + 5-MeO-DMT; empty bars). Data represent Mean + SEM values of triplicate measurements of three independent donors.
Asterisk indicates statistical significance (p,0.05).
doi:10.1371/journal.pone.0106533.g004
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Figure 5. Effect of sigmar-1 gene silencing on the DMT-modified cytokine profile of LPS or polyI:C-activated moDCs. A: Validation of
siRNA knockdown by Western blot. MoDCs were transfected with negative control siRNA (ctrl siRNA) or with gene-targeting siRNA (sigmar-1 siRNA),
or left untreated (non-transfected, NT). B–C: Non-treated, 24 h ctrl siRNA-only, and 24 h targeting siRNA-only treated cells were used as negative
controls (black bars). Red bars represent 24 h 500 ng/ml LPS-treated cells, while white bars show ctrl siRNA and 1 h DMT pre-treated cells activated
with LPS for one day. Grey (NN-DMT) and checkered bars (5-MeO-DMT) demonstrate 1 h DMT pre-treated and then 24 h LPS activated sigmar-1
knockdown cells. D–E: MoDCs were treated as in Fig5B–C. Here, cell activation was performed with a 24 h 20 mg/ml polyI:C treatment. Blue bars
Sigmar-1-Dependent Immunomodulatory Effects of NN-DMT and 5-MeO-DMT
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Differences were considered to be statistically significant at p
values ,0.05 (*).
Results
Expression of sigmar-1 in resting and activated human
primary myeliod cells
Sigmar-1 is an intracellular receptor that is located on the
mitochondria-associated endoplasmic reticulum membrane [7]. It
has already been detected in various neuronal cell types and brain
macrophages (microglia) of rodents [24,25], but little is known
about its expression in other immune cells. We first sought to
monitor the expression of sigmar-1 in human primary myeloid
cells (Figure 1) and found that sigmar-1 was expressed in primary
human blood monocytes and its expression increased during the
differentiation process toward macrophages and moDCs shown by
the increasing levels of sigmar-1 protein in both monocyte-derived
macrophages (moMACs) and moDCs (Figure 1A and 1B).
Interestingly, we could not detect measurable levels of sigmar-2
mRNA or protein in these samples derived from the same donors
(data not shown). Similar to previous results obtained with murine
microglia we also detected high levels of sigmar-1 protein in
human moMACs [24,25]. Since the expression and function of
sigmar-1 has already been established in macrophages, and
moDCs showed comparable levels of sigmar-1 to moMACs, in
our further studies we focused on moDCs. Taken the versatile
immunomodulatory potential of this regulatory cell type we first
addressed the question whether inflammatory conditions could
alter the expression of sigmar-1 in moDCs. To mimic inflamma-
tion and infection by pathogenic signals we treated moDCs with
high-dose bacterial lipopolysaccharide (LPS) or the viral nucleic-
acid analogue polyinosinic: polycytidylic acid (polyI:C) to elicit
strong inflammatory responses via TLRs and RLRs, respectively
[23,26]. Surprisingly enough, neither LPS nor polyI:C treatment
could cause alteration in the expression level of the sigmar1 gene
(Figure 1C) and protein (Figure 1D) in moDCs. Statistical analysis
of four independent experiments performed with cells of different
blood donors revealed no significant differences in sigmar-1
protein expression following 24 h LPS or polyI:C activation as
compared to the non-treated control cells indicating no direct
respose to these stimuli (Figure 1E).
NN-DMT and 5-MeO-DMT treatment inhibits
inflammatory but boosts anti-inflammatory responses in
LPS or polyI:C-stimulated moDCs
Based on the detectable levels of sigmar-1 in moDCs (Figure 1)
we next tested the effects of NN-DMT and 5-MeO-DMT
treatments on the cytokine profile of activated moDCs. Using
different time points and concentrations of DMT (Figure S1) we
were able to optimize the treatment protocol and found that a 1 h
pre-treatment with NN-DMT or 5-MeO-DMT was more efficient
to modulate TNF-a and IL-10 secretion than the co-administra-
tion of these agents with LPS or polyI:C (Figure S1A and S1B).
This phenomenon is presumably due to the time scale required for
the transportation and accumulation of DMT close to sigmar-1
sites in the cytoplasm of moDCs. We also found that 100 mM
DMT, an achievable serum concentration reported by previous
in vivo human [27] and animal studies [28], was optimal for
modulating TNFa levels in activated moDCs and was used in
further experiments (Figure S1C). Pre-treatment of LPS-activated
moDC with either NN-DMT or 5-MeO-DMT strongly reduced
the mRNA (Figure 2A) and the secreted levels (Figure 2B) of the
pro-inflammatory cytokines IL-1b, IL-6, TNF-a, and also the
chemokine IL-8/CXCL8. Decreased expression levels of these
soluble regulators was consistently lower in DMT+LPS treated
cells as compared to the LPS-activated control (Figure 2).
Conversely, in DMT pre-treated cells the expression and
production of the anti-inflammatory cytokine IL-10 was signifi-
cantly higher than in LPS-treated moDCs (Figure 2A and 2B). No
significant differences in the modulatory effects of NN-DMT and
5-MeO-DMT could be detected at equal working concentrations
(Figure 2B), and a similar pattern of cytokine profiles of both LPS
and polyI:C-stimulated moDCs was found. However, DMT pre-
treated and polyI:C-activated cells had lower mRNA expression
(Figure 3A) and secretion (Figure 3B) of pro-inflammatory cyto-
kines and chemokines than the respective polyI:C-only controls.
Similar to the DMT+LPS co-treatment experiments, expression
and production of IL-10 was significantly higher in DMT+polyI:C
treated cells than in cells treated with polyI:C alone (Figure 3).
The modulation of cytokine expressions was of similar extent in
cases of DMT and 5-MeO-DMT (Figure 3B). Additionally, levels
of the anti-inflammatory cytokine TGFb also elevated moderately,
though not significantly, when DMT co-treatments were applied
with LPS or polyI:C stimuli (data not shown). These results reflect
to the strong inhibitory capacity of NN-DMT and 5-MeO-DMT
on inflammatory responses in moDC when co-administered with
ligands of innate immune receptors. Taken the high migratory
potential and inflammatory nature of moDCs our results strongly
suggest that important functional activities of these cells can be
intervened by using NN-DMT and 5-MeO-DMT as pharmaco-
logical modulators.
DMT pre-treatment of pathogen-activated human
moDCs inhibits their capacity to prime autologous naive
T helper 1 (Th1) and T helper 17 (Th17) cells
Our results showed that short-term DMT pre-treatment of LPS
or polyI:C activated moDCs are able to suppress innate pro-
inflammatory responses but concommitantly promote IL-10 se-
cretion (Figures 2 and 3). Next we sought to investigate the
functional consequences of these cellular responses upon patho-
genic challenge by testing moDC-mediated T-cell polarization.
Previous reports showed that ligand specific stimulation of sigmar-
1 is able to increase LPS-induced serum IL-10 levels while inhibit
IFNc-dependent graft-versus-host response in mice [10,11]. It is
well known that polarization of adaptive ’’inflammatory’’ Th1
response is induced and supported by IFNc, while it is directly
inhibited by IL-10, a typical effector molecule of regulatory T-
cells. Th17, another inflammatory CD4+ helper T-cell type, is
known to strongly promote inflammation and recruitment of other
inflammatory cell types. The essential role of Th1 and Th17 cells
in the development of inflammatory conditions in both the central
nervous system and peripheral tissues in the context of infection
and autoimmunity has been studied in various animal models and
also in clinical studies [29–31]. We presumed that the opposing
effects of upregulated IL-10 and inhibited secretion of inflamma-
tory cytokines achieved by DMT administration might result in an
unique T cell response. To test this hypothesis, we co-cultured
naive autologous CD4+ T cells with pathogen-activated moDCs,
represent polyI:C-only stimulation as positive control. Results are shown as Mean 6 SEM of three independent donors. (*) represents p values ,0.05.
Differences are significant (p,0.05) in all cases of specific activation (LPS or polyI:C) versus control cells (no treatment, ctrl siRNA, sigmar-1 siRNA).
doi:10.1371/journal.pone.0106533.g005
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Figure 6. Sigmar-1 gene knockdown abrogates the inhibitory effect of tryptamines on the Th1/Th17 cell-activating capacity of
pathogen-activated moDCs. Cells were co-cultured and activated, and the number of IFNc or IL-17 secreting T cells was assessed by ELISPOT as in
Figure 4. A–B: Red bars represent E. coli-loaded DCs co-cultured with autologous naive CD4+ T cells. White bars show ctrl siRNA and 1 h tryptamine
pre-treated cells prior to a 24 h E. coli activation and subsequent T cell co-culturing. Grey (NN-DMT) and checkered bars (5-MeO-DMT) demonstrate
1 h tryptamine pre-treated and then 24 h E. coli activated sigmar-1 knockdown cells subsequently co-cultured with T cells as in Materials and
Methods. C–D: The same setup was applied as in Fig6A–B, however, in this case inactivated influenza virus (IV) was added to moDCs as antigen
stimulation. Blue bars show moDCs incubated with influenza-only for 24 h and then co-cultured with T cells (positive control). Data represent Mean +
Sigmar-1-Dependent Immunomodulatory Effects of NN-DMT and 5-MeO-DMT
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and measured the number of activated IFNc (Th1) and IL-17
(Th17) secreting effector T cells by ELISPOT assays (Figure 4). In
this experimental setting the common infectious agents influenza
virus and Escherichia coli (E. coli), both known to cause severe
CNS inflammations, were used as provoking agents [32–34].
Activation of moDCs with heat-killed E. coli resulted in strong
Th1 (Figure 4A) and Th17 (Figure 4B) responses, but both effector
T cell read-outs were markedly affected when NN-DMT or 5-
MeO-DMT pre-treatments were applied. The Th1 and Th17
priming capacity of moDCs in the presence of NN-DMT or 5-
MeO-DMT was significantly lower than in the abscence of these
drugs (Figure 4A and 4B). Similar results were obtained when the
stimulated moDCs were challenged with inactivated influenza
virus. DMT pre-treated and influenza-loaded moDCs were able to
activate a significantly lower number of Th1 (Figure 4C) and
Th17 cells (Figure 4D) as compared to influenza-only treated
moDCs. These findings show that NN-DMT and 5-MeO-DMT
can potently inhibit the processing and/or presentation of
bacterial and viral peptide antigens by moDCs, and thus block
Th1 and Th17 responses.
NN-DMT and 5-MeO-DMT modulate the cytokine
production and T cell-priming capacity of moDCs in a
sigma-1 receptor dependent manner
After demonstrating the inhibitory effect of NN-DMT and 5-
MeO-DMT on the inflammatory cytokine production (Figures 2
and 3) and CD4+ helper T cell-priming capacity of moDCs
induced by various inflammatory stimuli (Figure 4), we aimed to
test whether sigmar-1 plays a role in these processes. NN-DMT
has been described as a natural endogenous ligand for sigmar-1,
and its closely related naturally occuring analogues, such as
bufotenine or 5-MeO-DMT have also been proposed as possible
sigmar-1 agonists [16]. To clarify the immunomodulatory role of
sigmar-1 in moDC functional activities and to check its
contribution to the observed immunomodulatory effects we
performed sigmar1 gene knock-down experiments. Specific
silencing of sigmar1 gene expression resulted in a .95% (64%,
n = 3) of downregulation of the sigmar-1 protein as compared to
non-transfected and scrambled siRNA controls (Figure 5A). Using
the same cell activation protocols as in Figures 2 and 3, we found
that specific silencing of sigmar-1 ablated the modulatory potential
of NN-DMT and 5-MeO-DMT on TNFa (Figure 5B) and IL-
10 secretion (Figure 5C) by moDCs upon LPS activation. In a
similar experimental setup, sigmar-1 knock-down in polyI:C
activated moDCs almost completely abrogated the modulatory
potential of NN-DMT and 5-MeO-DMT on TNF-a (Figure 5D)
and IL-10 cytokine production (Figure 5E). We also tested the
effects of sigmar-1 gene expression silencing on moDC-mediated
helper T cell responses and found that downregulation of sigmar-1
resulted in significantly less inhibition of E. coli mediated Th1
(Figure 6A) and Th17 responses (Figure 6B) by dimethyltrypta-
mines than in controls. Similarly, siRNA-based silencing of
sigmar-1 expression was associated with decreased modulatory
capacity of NN-DMT and 5-MeO-DMT on priming Th1
(Figure 6C) and Th17 T-lymphocyte differentiation (Figure 6D)
when co-cultured with virus-loaded moDCs. Interestingly, knock-
down of sigmar-1 combined with DMT pre-treatment did not
restore cytokine levels and the T cell priming capacity of moDCs
completely (Figures 5 and 6) raising the possibility, that other
receptors and/or mechanisms may also contribute to the moDC
modulatory function of dimethyltryptamines. To further confirm
the involvement of sigmar-1 in this regulatory process, we used
another activation model in which we pretreated moDCs with a
selective and high affinity agonist of sigmar-1, i.e. PRE-084
hydrochloride, as a substitute of NN-DMT and 5-MeO-DMT.
The results revealed that specific ligation of sigmar-1 with PRE-
084 combined with LPS or polyI:C stimulation could by itself
modulate cytokine responses of human primary moDCs (Figure
S2) activated by LPS (Figure S2A and S2B) or polyI:C (Figure S2C
and S2D). PRE-084 pre-treatment also resulted in significant
inhibition of TNF-a production and increased IL-10 secretion that
could completely be abrogated by sigmar-1 silencing (Figure S2).
Discussion
Hallucinogenic trypamines are members of the indole alkaloid
family, the largest and most common class of alkaloids in the
Animal and Plant Kingdoms. NN-DMT and bufotenine, the
metabolic product of 5-MeO-DMT in mammals, have been
detected in animal and human blood, urine, cerebrospinal fluid,
brain, intestine and many other tissues suggesting that these
compounds may have important biological roles other than their
psychotropic and neuromodulatory properties [12,35–37].
The orphan receptor sigmar-1 has been shown to regulate many
physiological processes inculding cell survival and proliferation
[7,8]. The expression of sigma receptors is not limited to the brain
as high level expression was detected in mammalian liver, kidney,
gut and other tissues as well [5,38]. Sigmar-1 has also been
detected in immune cells mediating strong immunosuppressive
and anti-inflammatory effects [9–11]. It has recently been reported
that NN-DMT is an endogenous ligand for sigmar-1, and its
agonistic activity may be expanded to analogues, such as the
methoxy derivative 5-MeO-DMT [16]. However, very little is
known about the physiological functions of dimethyltryptamines in
human and the emphasis of contemporary research is mostly
related to understanding its psychedelic properties and to our best
knowledge, the biological effects of DMT via sigmar-1 has not
been investigated yet. In this study we adressed the question
whether sigmar-1 is expressed in human primary myeloid cells,
and if so, what is its functional role in human physiology.
According to our results, sigmar-1 is expressed in human
monocytes and its expression is increasing during the differenti-
ation process to macrophages and dendritic cells (Figure 1).
Although sigmar-1 expression has been documented in murine
macrophages [24,25], this is the first report on characterizing
sigmar-1 expression in resting and activated human myeloid
immune cells. To test the hypothesis that dimethyltryptamines
may have impact on immune cell functions through sigmar-1, we
tested the effects of DMT treatment on the cytokine profile of
activated moDCs. In these experiments we used the TLR3/RLR
ligand polyI:C and the TLR4 agonist LPS as strong inducers of
innate immune responses [18]. Our results revealed that NN-
DMT and 5-MeO-DMT pre-treatment potently inhibited pro-
inflammatory cytokine and chemokine (IL-1b, TNFa, IL-6, IL8)
expression in human moDCs stimulated by specific PRR ligands,
while had opposing effect on the mRNA and protein expression of
the anti-inflammatory cytokine IL-10 (Figures 2 and 3). Further-
more, NN-DMT and 5-MeO-DMT interfered with the activation
and polarization of naive T-lymphocytes toward Th1 and Th17
SEM values of triplicate measurements of three independent donors. Asterisk shows statistical significance (p,0.05). Differences are significant (p,
0.05) in cases of specific activation (E. coli or IV) versus T-cell controls.
doi:10.1371/journal.pone.0106533.g006
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effector T cells when co-cultured with E. coli or influenza-virus
loaded human moDCs (Figure 4). These results are in good
agreement with reports showing that sigmar-1 activation results in
elevated IL-10, decreased IFNc and GM-CSF levels, and
inhibition of lymphocyte proliferation in mice [9–11]. The results
also demonstrated for the fist time that NN-DMT and 5-MeO-
DMT have the capability to inhibit the polarization of human
moDC-primed CD4+ T helper cells towards inflammatory Th1
and Th17 effector lymphocytes in infectious/inflammatory
settings. This is of particular importance, since Th1 and Th17
cells and the cytokines they secrete are key players in the etiology
and symptomatology of many chronic inflammatory and autoim-
mune diseases of the CNS and other tissues [29,30,39]. Moreover,
the mobilization of innate immune mechanisms is also well
established in many psychiatric and neurological disorders [39]. In
neuropsychiatric research it is an increasingly accepted hypothesis
that a number of diseases affecting large populations, such as
Alzheimer’s, Parkinson’s disease, Major depression are caused by
chronic inflammation of the central nervous system. High-
resolution whole genome-wide association studies found significant
correlations between gene polymorphisms of innate immune
receptors and the frequency of late onset Alzheimer’s disease (AD)
[40,41]. It has also been demonstrated in mice that the ligand
specific activation of the mother’s TLRs and RLRs by LPS and
polyI:C results in decreased neurogenesis, cognitive deficits, and a
marked increase in the appearance and deposition of Ab
aggregates in the brain of the offspring [42,43]. Since blood-
derived monocytes were shown to be able to translocate to the
CNS [22], our results could expand the role of moDCs to a more
global context by suggesting their regulatory role under autoim-
mune or infectious inflammatory conditions in the brain.
In order to verify the contribution of sigmar-1 to the observed
immunomodulatory effects we used the approach of gene-specific
silencing. The results clearly demonstrated that downregulation of
sigmar-1 abrogated the immunomodulatory effects of both NN-
DMT and 5-MeO-DMT on cytokine secretion by innate immune
cells (Figures 5) and also inhibited the moDC-mediated polariza-
tion of Th1 and Th17 effector cells (Figure 6). Remarkably, knock-
down of sigmar-1 upon DMT pre-treatments could not restore
cytokine levels and the T cell priming capacity of moDCs
completely (Figures 5 and 6). These findings suggest that
additional mechanisms through which DMT could modulate
moDC functions may exist. NN-DMT and 5-MeO-DMT also
bind to the 5-HT2 (particularly 5-HT2A) and 5-HT1A serotonin
receptors with high affinity [44,45]. This agonism was suggested to
take part in psychological effects of dimethyltryptamines but may
also contribute to immunological functions, since the neurotrans-
mitter serotonin also exerts anti-inflammatory and immunoregu-
latory effects in DCs [46,47]. As the experiments with human cells
were performed in serum-free medium, the ’’serotonin back-
ground’’ effect can be excluded [48]. Thus, it is very likely that the
observed phenomenon is the result of DMT-mediated serotonin
receptor activation.
To further verify the role of sigmar-1 in the modulation of
moDC functions, we used the highly selective, high-affinity sigmar-
1 agonist PRE-084 hydrochloride as a substitute of NN-DMT/5-
MeO-DMT in the activation protocol. Similarly to NN-DMT and
5-MeO-DMT, PRE-084 treatment strongly interfered with TNF-
a and IL-10 secretion by LPS or polyI:C stimulated moDCs
(Figure S2). However, sigmar-1 knock-down could completely
restore cytokine levels in PRR-activated and PRE-084-treated cells
showing that sigmar-1 plays an essential role in the immunomod-
ulation of moDCs (Figure S2).
We conclude that the function of dimethyltryptamines may
extend the central nervous system activity and may play a more
universal role in immune regulation. Here we demonstrate for the
first time that NN-DMT and 5-MeO-DMT have potent
immunomodulatory effects on the functional activities of human
dendritic cells operating through the sigma-1 receptor. We also
show that DMT-mediated sigmar-1 activation can interfere with
both innate and adaptive immune responses. On the one hand, it
strongly decreases the levels of pro-inflammatory cytokines and
chemokines such as IL-1b, IL-6, TNFa and IL8, while upregulates
the production of the anti-inflammatory cytokine IL-10. On the
other hand, NN-DMT and 5-MeO-DMT pre-treatment of
pathogen-activated moDCs abolishes their capacity to initiate
adaptive immune responses mediated by inflammatory Th1 and
Th17 cells. These findings greatly expand the biological role of
dimethyltryptamines, which may act not only as neuromodulators
or psychedelics, but also as important regulators of both innate
and adaptive immunity. Thus, the DMT-sigmar-1 axis emerges as
a promising candidate for novel pharmacotherapies of chronic
inflammatory and autoimmune diseases.
Supporting Information
Figure S1 Time-dependence of the effects of sigmar-1
stimulation on moDC cytokine expression profiles. A-B:
Expression of TNFa and IL-10 genes in 8 h 500 ng/ml LPS-
stimulated moDCs. Tryptamines were added to the cells either at
the time of LPS treatment (co-administration; co-adm) or 1 h prior
to activation with LPS (1 h pre-treatment). Red bars represent
LPS-only treated positive controls. White bars demonstrate co-
treatments with 100 mM NN-DMT and 500 ng/ml LPS, while
black bars show co-treatments with same concentrations of 5-
MeO-DMT and LPS. Results are demonstrated as Mean 6 SEM
of three independent donors. C: Concentration-dependence of
tryptamines in hindering TNFa production of 24 h 500 ng/ml
LPS (red line) or 20 mg/ml polyI:C (blue line)-treated moDCs.
Non-activated controls are shown in green. Data of a represen-
tative experiment out of two are shown. (*) represents p values,
0.05.
(RAR)
Figure S2 Results of sigmar-1 gene silencing on the
PRE-084 hydrochloride-modulated cytokine profile of
moDCs activated by LPS or polyI:C. Non-treated, 24 h ctrl
siRNA-only, and 24 h targeting siRNA-only treated cells were
used as negative controls (black bars). Red and blue bars represent
24 h 500 ng/ml LPS (red) or 20 mg/ml polyI:C (blue)-treated
cells, while white bars show ctrl siRNA and 100 mM PRE-084
hydrochloride-treated cells 1 h prior to activation with LPS (A–B)
or polyI:C (C–D) for one day. Green bars demonstrate 1 h PRE-
084 hydrochloride pre-treated and then 24 h LPS (A–B) or
polyI:C (C–D) activated sigmar-1 knockdown cells. Results are
shown as Mean 6 SEM of three independent donors. (*)
represents p values,0.05.
(RAR)
Table S1 QPCR assay information.
(RAR)
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